Page 2 - Ladyn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ladyn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ladyn Today - Breaking & Trending Today

Dyne Therapeutics (NASDAQ:DYN) Trading Down 3%

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) traded down 3% on Thursday . The stock traded as low as $27.57 and last traded at $27.89. 552,733 shares were traded during mid-day trading, a decline of 75% from the average session volume of 2,206,098 shares. The stock had previously closed at $28.76. Wall Street Analysts […] ....

United States , Joshuat Brumm , Zurcher Kantonalbank Zurich Cantonalbank , Dirk Kersten , Piper Sandler , Securities Exchange Commission , Ameritas Investment Partners Inc , Royal Bank , Allspring Global Investments Holdings , Dyne Therapeutics Inc , Sphera Funds Management , Dyne Therapeutics , Get Free Report , Therapeutics Stock Down , Director Dirk Kersten , Exchange Commission , Investment Partners , Kantonalbank Zurich Cantonalbank , Global Investments Holdings , Dyne Therapeutics Daily , Nasdaq Dyn ,

Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Buy" by Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) has been given an average rating of “Buy” by the seven research firms that are covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month […] ....

United States , Joshuat Brumm , Stifel Nicolaus , Raymond James , Dirk Kersten , Piper Sandler , Securities Exchange Commission , Metlife Investment Management , Swiss National Bank , Charles Schwab Investment Management Inc , Dimensional Fund Advisors , Dyne Therapeutics Inc , Dyne Therapeutics , Get Free Report , Exchange Commission , Director Dirk Kersten , National Bank , Life Investment Management , Fund Advisors , Schwab Investment Management , Get Free , Dyne Therapeutics Daily , Nasdaq Dyn ,

Chardan Capital Increases Dyne Therapeutics (NASDAQ:DYN) Price Target to $31.00

Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target hoisted by Chardan Capital from $20.00 to $31.00 in a research note issued to investors on Friday, Stock Target Advisor reports. The brokerage currently has a buy rating on the stock. Several other research firms have also weighed in on DYN. StockNews.com upgraded shares of […] ....

United States , Piper Sandler , Raymond James , Oxana Beskrovnaya , Dirk Kersten , Stifel Nicolaus , Securities Exchange Commission , Dyne Therapeutics Inc , Blackrock Inc , Fcpm Iii Services , Goldman Sachs Group Inc , Vr Adviser , Dyne Therapeutics , Free Report , Chardan Capital , Stock Target Advisor , Moderate Buy , Get Free Report , Exchange Commission , Director Dirk Kersten , Goldman Sachs Group , Sachs Group , Dyne Therapeutics Daily , Nasdaq Dyn , Boost Price Target ,

Dyne Therapeutics (NASDAQ:DYN) Price Target Raised to $31.00

Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price objective increased by Chardan Capital from $20.00 to $31.00 in a research report sent to investors on Friday morning, Stock Target Advisor reports. Chardan Capital currently has a buy rating on the stock. Several other equities research analysts have also recently issued reports on the stock. […] ....

United States , Stifel Nicolaus , Zurcher Kantonalbank Zurich Cantonalbank , Piper Sandler , Dirk Kersten , Richard William Scalzo , Dyne Therapeutics Inc , Sphera Funds Management , Allspring Global Investments Holdings , Securities Exchange Commission , Royal Bank , Ameritas Investment Partners Inc , Dyne Therapeutics , Free Report , Chardan Capital , Stock Target Advisor , Moderate Buy , Get Free Report , Director Dirk Kersten , Exchange Commission , William Scalzo , Investment Partners , Kantonalbank Zurich Cantonalbank , Global Investments Holdings , Dyne Therapeutics Daily , Nasdaq Dyn ,